An updated dose-response analysis in Hodgkin's disease

Area of Science:

• Radiation Oncology
• Clinical Oncology
• Medical Physics

Background:

• Early-stage Hodgkin's disease (HD) has a high cure rate with radiotherapy.
• A controversy exists regarding optimal radiotherapy doses for local control, with recommendations ranging from 36 Gy to 44 Gy.
• Previous dose recommendations were based on older kilovoltage data and may not reflect current practices or varying tumor burdens.

Purpose of the Study:

• To re-evaluate the dose-response relationship for radiotherapy in Hodgkin's disease using updated data.
• To determine optimal radiotherapy doses for achieving >95% local control across different disease burdens (subclinical, <6 cm, >6 cm).

Main Methods:

• Compiled and analyzed dose-control data from the 1960s to the 1990s.
• Utilized updated statistical methods on both original and modern megavoltage radiotherapy data.
• Performed specific analyses for subclinical disease and tumors categorized by size (<6 cm and >6 cm).

Main Results:

• Re-analysis of updated data indicates that 37.5 Gy with megavoltage radiotherapy achieves similar local control rates as the previously recommended 44 Gy.
• Specific doses for 98% in-field control were determined: 32.4 Gy for subclinical disease, 36.9 Gy for <6 cm disease, and 37.4 Gy for >6 cm disease.
• Original analysis suggested 44 Gy was needed for 98% control, highlighting the impact of updated data and techniques.

Conclusions:

• Modern megavoltage radiotherapy allows for reduced doses to achieve high local control rates in Hodgkin's disease.
• The findings provide evidence-based guidance for radiation oncologists to tailor radiotherapy prescriptions based on disease burden.
• This updated analysis refines dose recommendations, potentially minimizing treatment toxicity while maintaining efficacy.